486 related articles for article (PubMed ID: 11595703)
1. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer.
Ross JS; Kaur P; Sheehan CE; Fisher HA; Kaufman RA; Kallakury BV
Mod Pathol; 2003 Mar; 16(3):198-205. PubMed ID: 12640098
[TBL] [Abstract][Full Text] [Related]
3. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
4. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
6. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
7. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
Zhou CY; Yao JF; Chen XD
Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
9. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart.
Soini Y; Satta J; Määttä M; Autio-Harmainen H
J Pathol; 2001 Jun; 194(2):225-31. PubMed ID: 11400152
[TBL] [Abstract][Full Text] [Related]
10. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
12. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
[TBL] [Abstract][Full Text] [Related]
13. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma.
Bramhall SR; Neoptolemos JP; Stamp GW; Lemoine NR
J Pathol; 1997 Jul; 182(3):347-55. PubMed ID: 9349239
[TBL] [Abstract][Full Text] [Related]
14. MMP/TIMP imbalance in amniotic fluid during PROM: an indirect support for endogenous pathway to membrane rupture.
Fortunato SJ; Menon R; Lombardi SJ
J Perinat Med; 1999; 27(5):362-8. PubMed ID: 10642956
[TBL] [Abstract][Full Text] [Related]
15. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas.
Gakiopoulou H; Nakopoulou L; Siatelis A; Mavrommatis I; Panayotopoulou EG; Tsirmpa I; Stravodimos C; Giannopoulos A
Clin Cancer Res; 2003 Nov; 9(15):5573-81. PubMed ID: 14654538
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of lymph node and tumor matrix metalloproteinase expression in the analysis of metastatic periampullary tumors.
McKenna GJ; Meneghetti A; Chen YL; Mui AL; Ong C; Scudamore CH; McMaster WR; Owen DA; Chung SW
J Surg Oncol; 2005 Jun; 90(4):239-46. PubMed ID: 15906368
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in laryngeal cancer.
Danilewicz M; Sikorska B; Wagrowska-Danilewicz M
Med Sci Monit; 2003 Mar; 9(3):MT42-7. PubMed ID: 12640351
[TBL] [Abstract][Full Text] [Related]
19. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
20. [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior].
He DS; Chen MZ; Wang HJ; Ke CL; Yan C; Zheng H; Hong YS
Ai Zheng; 2002 Oct; 21(10):1124-8. PubMed ID: 12508658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
